QIAGEN N.V.
QGEN evidence brief
What we can confirm
- Market Cap:
- $8.77B
What it means
What to watch
Prepared research question
What matters most for QGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · QGEN
QIAGEN N.V. is a global molecular diagnostics company focused on sample and assay technologies, with a strategic emphasis on its QuantiFERON latent tuberculosis testing franchise and the expansion of its QIAstat-Dx syndromic testing menu.
Key risk: High debt level
Market Cap
$8.77B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 3 clinical trials for QIAGEN N.V..
QIAGEN N.V. is a global molecular diagnostics company focused on sample and assay technologies, with a strategic emphasis on its QuantiFERON latent tuberculosis testing franchise and the expansion of its QIAstat-Dx syndromic testing menu.
- QIAGEN reported cash & equivalents of $839.0M, shareholders' equity of $3,778.2M, and total debt of $1,654.4M as of 2025-12-31 [sec].
- The company is targeting steadier growth through 2027, leaning on new launches, Connect automation, and QIAstat-Dx menu expansion amid choppy demand [news · published 2026-05-28].
- QIAGEN launched a CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel for rapid bloodstream infection syndromic testing [news · published 2026-04-14].
- QIAGEN highlighted its molecular testing solutions supporting the public health response to the growing U.S. Cyclospora outbreak [news · published 2026-07-15].
- CEO Jonathan Pratt presented at the Morgan Stanley 24th Annual Global Healthcare Conference in September 2026 [news · published 2026-09-14].
What works
- Strong cash position of $839.0M as of 2025-12-31 provides financial flexibility for R&D and commercial expansion [sec].
- Expanding QIAstat-Dx menu into bloodstream infection testing addresses a high-need clinical area and may drive revenue growth [news · published 2026-04-14].
- Strategic focus on QuantiFERON latent tuberculosis testing, a well-established franchise, supports stable demand [news · published 2026-05-08].
What to weigh
- Total debt of $1,654.4M as of 2025-12-31 represents a significant leverage position that could constrain flexibility [sec].
- Demand environment described as 'choppy,' indicating potential revenue volatility in the near term [news · published 2026-05-28].
- The company faces competitive pressure from multiple oncology-focused trials by large pharma firms, though QIAGEN's core diagnostics business is not directly in that space [competitor_trial].
From the filings
Quoted directly from source documents.
QIAGEN's growth strategy through 2027
“QGEN targets steadier growth through 2027, leaning on new launches, Connect automation and QIAstat-Dx menu expansion amid choppy demand.”
News · May 28, 2026
Launch of QIAstat-Dx panel for bloodstream infections
“QIAGEN N.V. had announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.”
News · April 14, 2026
Risks & what to watch (2)›
Key risks
- High debt level — Total debt of $1,654.4M as of 2025-12-31 may limit financial agility [sec].
- Choppy demand environment
What to watch
- Adoption and revenue contribution of the new QIAstat-Dx BCID GPF Plus AMR Panel for bloodstream infections [news · published 2026-04-14].
- Progress of QuantiFERON latent tuberculosis testing franchise and any competitive developments [news · published 2026-05-08].
- Impact of Connect automation and menu expansion on growth trajectory through 2027 [news · published 2026-05-28].
- Any further strategic updates from CEO Jonathan Pratt following the Morgan Stanley conference [news · published 2026-09-14].
Sources: Competitor trials · News · Generated October 13, 2026 · How we verify sources →
Run QIAGEN N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available QIAGEN N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 3.5%
- Days to cover
- 3.3
- Shares short
- 6,353,079
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
QGEN short interestGovernance
Frequently asked questions
What is the AI investment thesis for QIAGEN N.V.?
QIAGEN N.V. is a global molecular diagnostics company focused on sample and assay technologies, with a strategic emphasis on its QuantiFERON latent tuberculosis testing franchise and the expansion of its QIAstat-Dx syndromic testing menu.
Who is the CEO of QIAGEN N.V.?
Mr. Jonathan M. Pratt is the chief executive officer of QIAGEN N.V. (QGEN).
Where is QIAGEN N.V. headquartered?
QIAGEN N.V. (QGEN) is headquartered in Venlo, Netherlands.
What therapeutic areas does QIAGEN N.V. focus on?
QIAGEN N.V. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.